A number of other research analysts have also recently commented on CRSP. Zacks Investment Research upgraded CRISPR Therapeutics from a hold rating to a buy rating and set a $58.00 price target for the company in a research note on Friday. BidaskClub upgraded CRISPR Therapeutics from a buy rating to a strong-buy rating in a research note on Monday. ValuEngine upgraded CRISPR Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 28th. SunTrust Banks reiterated a buy rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Friday, March 9th. Finally, Barclays increased their price target on CRISPR Therapeutics from $29.00 to $59.00 and gave the company an overweight rating in a research note on Wednesday, March 7th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $63.10.
Shares of CRISPR Therapeutics opened at $56.78 on Friday, according to Marketbeat. CRISPR Therapeutics has a 52 week low of $52.10 and a 52 week high of $56.68. The firm has a market capitalization of $2.49 billion, a PE ratio of -33.20 and a beta of 3.58.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.05. CRISPR Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The company had revenue of $1.36 million during the quarter, compared to analysts’ expectations of $3.64 million. During the same period in the prior year, the company earned ($0.54) EPS. CRISPR Therapeutics’s revenue was down 49.6% compared to the same quarter last year. sell-side analysts predict that CRISPR Therapeutics will post -2.6 earnings per share for the current fiscal year.
In related news, Director Thomas Woiwode sold 222,258 shares of the stock in a transaction on Friday, April 27th. The stock was sold at an average price of $50.11, for a total value of $11,137,348.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Versant Venture Capital V, L.P sold 22,841 shares of the stock in a transaction on Tuesday, April 24th. The shares were sold at an average price of $50.99, for a total value of $1,164,662.59. The disclosure for this sale can be found here. Insiders sold 506,609 shares of company stock valued at $25,506,022 over the last 90 days. 37.70% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Versant Venture Management LLC acquired a new stake in CRISPR Therapeutics during the 1st quarter worth about $210,551,000. NEA Management Company LLC grew its holdings in CRISPR Therapeutics by 8.2% during the 1st quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock worth $159,275,000 after acquiring an additional 263,736 shares during the period. Farallon Capital Management LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $20,160,000. Franklin Resources Inc. grew its holdings in CRISPR Therapeutics by 8.9% during the 4th quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after acquiring an additional 65,200 shares during the period. Finally, Global Thematic Partners LLC grew its holdings in CRISPR Therapeutics by 11.2% during the 4th quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after acquiring an additional 63,611 shares during the period. Institutional investors and hedge funds own 36.73% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.